Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.18 is 13% below its 5-year average of 0.21, near the high end of its 5-year range (-66789.49–15.64).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -13354.20.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.18.
DEBT TO EQUITY RATIO
0.18
DEBT TO EQUITY RATIO AVG TTM
-13354.20
DEBT TO EQUITY RATIO AVG 3Y
-6676.91
DEBT TO EQUITY RATIO AVG 5Y
0.21
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
-13.18%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.17
median of 346 covered companies
CURRENT VS SECTOR MEDIAN
+6.58%
vs the sector median at left
20/20 Biolabs Inc.
Market Cap
$4.32M
Debt to Equity Ratio
0.18
TTM Avg
-13354.20
3Y Avg
-6676.91
5Y Avg
0.21
Market Cap
$4.41M
Debt to Equity Ratio
0.11
TTM Avg
0.30
3Y Avg
4.92
5Y Avg
3.36
Market Cap
$4.42M
Debt to Equity Ratio
0.90
TTM Avg
0.35
3Y Avg
0.23
5Y Avg
0.29
Market Cap
$4.46M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$3.94M
Debt to Equity Ratio
0.70
TTM Avg
0.62
3Y Avg
0.55
5Y Avg
2.94
Market Cap
$4.79M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$4.96M
Debt to Equity Ratio
1.57
TTM Avg
0.64
3Y Avg
1.33
5Y Avg
1.33
Market Cap
$4.99M
Debt to Equity Ratio
0.36
TTM Avg
0.26
3Y Avg
0.18
5Y Avg
0.25
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.32M | 0.18 | -13354.20 | -6676.91 | 0.21 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | 0.11 | 0.30 | 4.92 | 3.36 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | 0.90 | 0.35 | 0.23 | 0.29 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | 0.00 | 0.00 | 0.00 | 0.00 |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | 0.70 | 0.62 | 0.55 | 2.94 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | 0.00 | 0.00 | 0.02 | 0.02 |
| CalciMedica, Inc. (CALC)vs › | $4.85M | 0.00 | 0.00 | 0.00 | 0.92 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | 1.57 | 0.64 | 1.33 | 1.33 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | 0.36 | 0.26 | 0.18 | 0.25 |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
Debt/Equity
0.18
Current Ratio
1.99
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.18 |
| 2026-03-31 | 0.34 |
| 2025-12-31 | -66789.49 |
| 2025-09-30 | 15.64 |
| 2025-06-30 | 2.35 |
| 2024-12-31 | 0.99 |
| 2024-09-30 | 0.00 |
| 2023-12-31 | 0.29 |
| 2023-09-30 | 0.29 |
| 2023-06-30 | 0.34 |
| 2023-03-31 | 0.29 |
| 2022-12-31 | 0.15 |
| 2022-09-30 | 0.15 |
| 2022-06-30 | 0.12 |
| 2021-12-31 | 0.18 |
| 2021-09-30 | 0.18 |
